Thu, Jul 31, 2014, 4:08 PM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

Red Hat, Inc. Message Board

green_side_up 6 posts  |  Last Activity: Jul 25, 2014 3:06 PM Member since: Nov 2, 2011
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • What a joke! And the FED says small-cap biotech is overvalued. Last time I checked, the FED didn't run a biotech company, own a biotech hedge fund, or have biotech analysts on staff. The FED should stick to Economics and HTBX management should spend some time educating the biotech hedge funds about their platform technology...clearly the message by the HTBX investment bankers didn't do the job.

  • Reply to

    Most overvalued biotech company

    by aecooter33 Jul 14, 2014 1:21 PM
    green_side_up green_side_up Jul 25, 2014 11:14 AM Flag

    You couldn't be more wrong. I hope you short. FMI is signficantly undervalued. The company is changing the entire landscape of the cancer patient dynamic. It's software / testing service platform changes patient care in nearly 1/3 of all cancer patients...that is a staggering number at this early stage in patient specific care. As testing becomes more dynamic, this number is only going to grow. Do you realize how many billions of dollars FMI's platform will save once it becomes first-line defense! FMI is discussing this very issue with regulators.

    If it executes, FMI will be a 100-bagger.

  • This week's news that fish oil helps slow Dementia and Alzheimer's Disease and the past few weeks news that Triglycerides play a vital role in Heart Disease bodes extremely well for the inherent value of Vascepa and its potential to become a wonder drug. Given it's very strong clinical data, enhanced market opportunity, unique product offering, and tiny market capitalization, look for big pharma to buyout AMRN in the next few months or sooner...

    Sentiment: Strong Buy

  • green_side_up green_side_up Jun 27, 2014 6:06 PM Flag

    Look for a big move up in the next 1-2 months as cardiologists digest last week's news of the 40% lower risk by reducing triglycerides, a direct improvement seen from taking Vascepta. AMRN will see $2 shortly and finish 2014 around $5. Usually takes a few weeks for medical news to get around because not all physicians stay abreast of the latest medical news (sad, but true)....so, scripts numbers will rise as the news changes how cardiologists treat patients. In the hands of big pharma, Vascepta would do extremely well. Expect a takeout.

  • green_side_up by green_side_up Jun 17, 2014 3:37 AM Flag

    Another press release of so-called positive news...a new patent, another cohort of its lead cancer drug, more uses for its new antibiotic, etc., etc., etc.

    CTIX goes nowhere. Market cap of $180 million despite three potential blockbuster drugs in development. Doesn't make much sense does it? Nope. And, that should raise a red flag. The market doesn't care about any of these types of press releases. The market wants to know whether any of these drugs work. And, so far, we don't know much of anything. Sure, Kevatrin is in its 8th cohort and is increasing its dosage...but there are plenty of things that could do that...like a concoction of vitamins. The real and only question the market cares about is whether Kevatrin (and the other two drugs in the pipeline for that matter) is creating any statistically significant response rates among its patients. Until that time, all of this type of stuff is management fluff.

    And, let's also keep in mind that if Kevatrin was really the so-called magic bullet...and patients had amazing response rates, you can bet that somebody would hear about it before everyone else....somebody would buy a massive amount of this stock or the options. So, watch the volume...there will be a big pick-up in volume the day before great results are announced, if any, as the smart money will hear about the amazing recovery of John Smith from the hospital bed in Dana Farber and get into the stock before the press release carrying the information to the public. That's how things work.

    Ignore Ctixers fluff too...just watch the CTIX price and volume.

  • green_side_up by green_side_up May 9, 2014 11:09 AM Flag

    This stock is trading like both Einhorn and Loeb bailed...that's the problem with waiting for quarterly filings...we just don't know. But, the action is HORRIBLE. Need more insider buying ASAP!

RHT
58.12-0.17(-0.29%)4:01 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.